ApoB and Non-HDL Cholesterol in Cardiovascular Risk Assessment

Definition and Pathophysiology

Apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C) are complementary measures of atherogenic lipoprotein burden. Their clinical importance arises from the causal role of low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoproteins in atherosclerotic cardiovascular disease (ASCVD).

Atherosclerosis develops through the progressive deposition and retention of LDL-C and other apoB-containing lipoproteins within the arterial wall. This initiates inflammatory reactions that promote plaque formation and progression. As the burden of retained atherogenic particles accumulates over time, the probability of an acute atherosclerotic cardiovascular event increases.

Non-HDL Cholesterol

Non-HDL-C is calculated as:

Non-HDL-C = total cholesterol − HDL-C

It represents the cholesterol contained in all apoB-containing lipoproteins, including:

• LDL

• Intermediate-density lipoprotein (IDL)

• Lipoprotein(a) [Lp(a)]

• Very-low-density lipoprotein (VLDL)

• Chylomicrons and other triglyceride-rich particles

Thus, non-HDL-C provides a broader estimate of atherogenic cholesterol than LDL-C alone. It is particularly informative when triglyceride-rich lipoproteins are increased, as commonly occurs with obesity, diabetes, prediabetes, insulin resistance, metabolic syndrome, and hypertriglyceridaemia.

Because triglyceride-rich particles contribute additional cholesterol—often approximately 30 mg/dL—non-HDL-C treatment goals are generally approximately 30 mg/dL higher than corresponding LDL-C goals.

Apolipoprotein B

ApoB is the principal structural apolipoprotein of atherogenic lipoproteins. Each atherogenic lipoprotein particle carries one apoB molecule. Consequently, the plasma apoB concentration approximates the number of circulating atherogenic particles rather than the amount of cholesterol carried within them.

Most apoB-containing particles are LDL particles, with smaller contributions from VLDL, IDL, and Lp(a). ApoB therefore reflects particle number, whereas LDL-C and non-HDL-C primarily reflect cholesterol content.

The amount of cholesterol carried by individual particles varies according to particle size and composition. As a result, apoB and cholesterol measures may be discordant. A patient may have:

• Relatively high apoB despite normal or low LDL-C or non-HDL-C

• Relatively low apoB despite higher cholesterol concentrations

When apoB is discordant with LDL-C or non-HDL-C, cardiovascular risk may be misestimated if cholesterol measures alone are used. Risk in these circumstances appears to track more closely with apoB. Discordantly high apoB is especially associated with metabolic syndrome and mildly elevated triglycerides, even when LDL-C is normal or low.

Clinical Significance

Non-HDL-C is strongly associated with cardiovascular risk for both initial and on-treatment assessment. In most studies, its association with cardiovascular risk is at least as strong as, and often stronger than, that of LDL-C.

ApoB has also been more closely associated with cardiovascular risk than LDL-C in many studies, although the relative advantage of apoB over non-HDL-C or standard lipid testing remains unsettled. In a large population study, LDL-C, non-HDL-C, and apoB showed similar baseline risk associations, emphasizing that the three measures are closely related in many patients.

The practical distinction is that:

• LDL-C estimates cholesterol within LDL particles.

• Non-HDL-C estimates cholesterol within all apoB-containing particles.

• ApoB estimates the number of atherogenic particles.

For most individuals in whom these measurements are concordant, their clinical utility is similar. Their greatest incremental value occurs when triglycerides are elevated, LDL-C is very low, or cardiometabolic abnormalities make LDL-C an incomplete representation of atherogenic burden.

Clinical Presentation and Symptoms

ApoB elevation and increased non-HDL-C are laboratory abnormalities and do not produce specific symptoms. Their clinical relevance lies in the associated risk of ASCVD rather than in a characteristic clinical syndrome.

Patients may therefore present:

• Without symptoms, during cardiovascular risk screening

• With established coronary, cerebrovascular, or peripheral arterial disease

• With diabetes, obesity, metabolic syndrome, insulin resistance, or hypertriglyceridaemia

• With a family history suggestive of inherited dyslipidaemia or premature coronary disease

A normal or modest LDL-C level does not exclude substantial atherogenic risk when triglyceride-rich lipoproteins, remnants, or apoB-containing particles are increased.

Evaluation and Physical Examination

Evaluation begins with assessment of the overall cardiovascular risk context. Important clinical features include:

• Known ASCVD

• Diabetes mellitus

• Chronic kidney disease

• Familial hypercholesterolaemia or another genetic lipid disorder

• Hypertension and other cardiovascular risk factors

• Obesity, particularly abdominal obesity

• Metabolic syndrome or insulin resistance

• Hypertriglyceridaemia

• Premature coronary disease in the patient or family

• Risk modifiers, including arterial plaque burden where appropriate

For asymptomatic adults aged 40–89 years without established ASCVD, diabetes, chronic kidney disease, familial hypercholesterolaemia, or genetic or rare lipid and blood-pressure disorders, European guidance recommends estimation of 10-year risk using the region-specific SCORE2 or SCORE2-OP algorithms.

Physical examination findings are not specific for apoB elevation or increased non-HDL-C. The source material does not provide a distinct examination protocol or characteristic physical signs for these abnormalities.

Diagnostics

Standard Lipid Profile

Standard lipid testing should include:

• Total cholesterol

• LDL-C

• HDL-C

• Triglycerides

Lipid sampling may be fasting or non-fasting for general cardiovascular risk screening. Non-fasting testing has similar prognostic value to fasting testing and is suitable for routine assessment. Particular care is required when interpreting calculated LDL-C in patients with diabetes, metabolic syndrome, or hypertriglyceridaemia.

LDL-C Calculation

When appropriate, LDL-C may be estimated using the Friedewald formula:

LDL-C = total cholesterol − (triglycerides/5) − HDL-C

This approach is reasonably accurate when the sample is fasting and triglycerides do not exceed approximately 200 mg/dL. By convention, the formula should not be used when triglycerides exceed 400 mg/dL. Direct LDL-C measurement is available through several laboratory methods.

Non-HDL-C Measurement

Non-HDL-C is readily derived from the standard lipid profile:

Non-HDL-C = total cholesterol − HDL-C

It does not require triglycerides to be below 400 mg/dL and remains accurate in the non-fasting setting. These features make it particularly useful when triglycerides are elevated or when calculated LDL-C may be unreliable.

ApoB Measurement

ApoB can be measured directly in plasma. It may be used:

• As an additional risk marker

• As a secondary treatment target after LDL-C goals have been addressed

• As an alternative primary lipid measure when available

• In patients with high triglycerides, diabetes, obesity, metabolic syndrome, or very low LDL-C

The material does not provide a specific laboratory assay method, reference interval, or universal apoB treatment target.

Lp(a)

Lp(a) is an independent, highly heritable ASCVD risk factor. It may assist risk stratification, particularly in individuals with:

• Very high LDL-C

• Premature coronary artery disease

• A strong family history of coronary disease

The source material recommends that Lp(a) be measured at least once during a lifetime, particularly in these settings. It does not provide an Lp(a)-specific treatment target.

Biomarkers and Laboratory Findings

Interpretation of Key Lipid Measures

Cardiometabolic Dyslipidaemia

Diabetes and insulin resistance commonly produce an atherogenic lipid pattern characterized by:

• Increased apoB-containing particles

• Increased triglyceride-rich lipoproteins and remnants

• Reduced HDL-C

• Increased small, dense LDL particles

In these circumstances, apoB measurement or non-HDL-C calculation may estimate risk more accurately than LDL-C alone. Poorly controlled diabetes, obesity, or moderate-to-severe hyperglycaemia may be associated with severe hypertriglyceridaemia, chylomicronaemia, and increased VLDL-C.

HDL-C

Although HDL-C is inversely associated with cardiovascular risk in observational studies, increasing HDL-C pharmacologically has not demonstrated clinical benefit. Very high HDL-C concentrations may paradoxically be associated with increased risk. HDL-C remains useful for risk estimation, but it should not be treated as a therapeutic target on the basis of the information provided.

Other Laboratory Assessment

In patients with established or suspected coronary artery disease, evaluation should include:

• Total cholesterol

• LDL-C

• HDL-C

• Triglycerides

• Serum creatinine or cystatin-C, with estimated glomerular filtration rate

• Glycated haemoglobin (HbA1c)

Before statin initiation, baseline testing should include:

• A fasting or non-fasting lipid panel

• Alanine aminotransferase

• Creatine kinase

Glucose should be monitored in statin-treated individuals who have risk factors for diabetes.

Routine screening for homocysteine is not recommended because interventions that lower homocysteine have not demonstrated clinical benefit.

Treatment and Management

General Principles

The primary objective is to reduce the burden of atherogenic lipoproteins, with LDL-C as the principal treatment target. Treatment intensity should be determined by total cardiovascular risk and the degree of LDL-C reduction required.

Greater absolute reductions in LDL-C produce greater cardiovascular risk reduction. Therefore, individuals at higher risk require more intensive therapy to achieve lower residual risk.

The principal management sequence is:

• Assess total cardiovascular risk.

• Identify established ASCVD, diabetes, chronic kidney disease, familial hypercholesterolaemia, or other high-risk conditions.

• Obtain the standard lipid profile and consider non-HDL-C, apoB, and Lp(a) according to clinical context.

• Address lifestyle and secondary causes.

• Initiate statin therapy when indicated.

• Add combination therapy if LDL-C goals are not achieved.

• Reassess LDL-C and, when relevant, non-HDL-C or apoB.

Lifestyle Intervention

Lifestyle modification is the foundation of ASCVD prevention. It may reduce LDL-C by approximately 10%–20%. Management should include dietary and exercise measures directed toward a healthy diet and ideal body weight.

In hypertriglyceridaemia, lifestyle measures and identification and treatment of secondary causes should precede pharmacological treatment. Dietary patterns containing linoleic acid and plant oils in place of animal fats are associated with reductions in LDL-C and triglyceride-rich lipoproteins and with cardiometabolic benefit.

Statins

Statins are the first-choice pharmacological treatment for LDL-C reduction. High-dose statin therapy can lower LDL-C by up to 50%. The cardiovascular benefit is related to the magnitude of LDL-C reduction and is not specific to statin therapy alone.

When LDL-C remains above the recommended goal, combination therapy may be required.

Combination Lipid-Lowering Therapy

Therapies that increase LDL clearance may be used in combination with statins. The material identifies the following options:

• Ezetimibe

• Bempedoic acid

• PCSK9 monoclonal antibodies

• Inclisiran

These therapies are used according to the required degree of LDL-C lowering, the presence of functional LDL receptors, patient characteristics, and patient preferences.

Medications that reduce LDL production, such as lomitapide and evinacumab, are reserved for patients with homozygous familial hypercholesterolaemia. Obicetrapib is identified as another emerging therapeutic approach.

Management of Residual Atherogenic Burden

Once LDL-C goals have been achieved, non-HDL-C or apoB may be used as secondary treatment targets, particularly when there are:

• Elevated triglycerides

• Obesity

• Metabolic syndrome

• Diabetes

• Very low LDL-C

This approach addresses residual risk from triglyceride-rich lipoproteins and other apoB-containing particles that may not be captured adequately by LDL-C.

Hypertriglyceridaemia

The initial strategy consists of:

• Lifestyle intervention

• Identification and correction of secondary causes

• Statin therapy to reduce ASCVD risk and achieve the LDL-C goal

After LDL-C has reached its goal, high-dose icosapent ethyl may be considered in patients at high risk. Fibrates lower triglycerides, but the evidence for macrovascular cardiovascular protection in statin-treated patients is unclear. They may provide benefits for microvascular disease.

Lp(a)-Related Risk

PCSK9 inhibitors lower Lp(a) by approximately 20%–25%, which may contribute to their overall therapeutic benefit. Apheresis can achieve a much greater degree of Lp(a) lowering, but targeted therapies remain under development. Niacin should not be used specifically to lower Lp(a), because randomized trials have not shown clinical benefit.

Guideline Recommendations

Risk Assessment

European prevention guidance recommends:

• SCORE2 or SCORE2-OP for asymptomatic adults aged 40–89 years without ASCVD, diabetes, chronic kidney disease, familial hypercholesterolaemia, or genetic or rare lipid or blood-pressure disorders.

• Priority management of all modifiable risk factors in individuals with ASCVD, diabetes, moderate-to-severe renal disease, genetic or rare lipid disorders, or high or very high calculated risk.

• Consideration of lifetime risk, frailty, polypharmacy, and patient preference when planning treatment.

Lipid Analyses

Guideline recommendations summarized in the source material include:

• LDL-C as the primary lipid measure for screening, diagnosis, and management.

• Triglycerides as part of routine lipid analysis.

• Non-HDL-C for risk assessment, particularly with high triglycerides, diabetes, obesity, or very low LDL-C.

• ApoB for risk assessment in the same clinical settings.

• ApoB as an alternative to LDL-C for screening, diagnosis, and management when available; it may be preferred over non-HDL-C in patients with high triglycerides, diabetes, obesity, or very low LDL-C.

• Non-HDL-C as a reasonable alternative treatment goal for all patients, especially those with hypertriglyceridaemia or diabetes.

• LDL-C as the primary treatment target, with non-HDL-C and apoB as secondary targets when residual atherogenic burden is a concern.

The American Heart Association/American College of Cardiology guidance identifies apoB ≥130 mg/dL and non-HDL-C ≥190 mg/dL as risk-enhancing factors that may influence discussions about initiating or intensifying statin treatment in borderline- or intermediate-risk primary prevention. ApoB testing is particularly suggested when triglycerides are ≥200 mg/dL.

Canadian guidance recommends following apoB or non-HDL-C particularly when triglycerides are ≥1.5 mmol/L.

LDL-C Goals

The summarized European recommendations specify the following goals:

These targets apply within the clinical settings described in the guideline summary, including high- and very-high-risk diabetes and selected apparently healthy individuals classified by SCORE2 or SCORE2-OP.

Monitoring of Therapy

A baseline fasting or non-fasting lipid panel should be obtained before statin therapy, together with alanine aminotransferase and creatine kinase.

The lipid response should be reassessed with a repeat fasting or non-fasting lipid panel within 1–3 months of treatment initiation. This assessment evaluates:

• Adherence

• Treatment response

• Percentage LDL-C reduction

• Achievement of the relevant LDL-C goal

• The need for treatment intensification

In patients with cardiometabolic risk factors, monitoring should also consider non-HDL-C or apoB. Glucose monitoring is appropriate in statin-treated individuals with risk factors for diabetes.

Long-term treatment should remain integrated with dietary and exercise interventions aimed at achieving a healthy diet and ideal body weight.

Prognosis and Follow-Up

Increased apoB and non-HDL-C indicate a greater burden of atherogenic particles and are associated with increased ASCVD risk. The relationship between non-HDL-C and cardiovascular risk is at least as strong as that of LDL-C, while apoB may provide superior risk discrimination when discordance exists between particle number and cholesterol content.

The prognostic significance is particularly important in patients with:

• Diabetes

• Obesity

• Metabolic syndrome

• Insulin resistance

• Hypertriglyceridaemia

• Very low LDL-C

• Increased triglyceride-rich lipoproteins or remnants

Lowering LDL-C reduces fatal and non-fatal myocardial infarction, ischaemic stroke, and ischaemic events in peripheral arterial territories. The absolute benefit depends on both baseline cardiovascular risk and the absolute reduction in LDL-C. Consequently, the same lipid reduction produces greater absolute benefit in patients at higher baseline risk.

Follow-up should include periodic reassessment of lipid parameters and cardiovascular risk, with particular attention to LDL-C as the primary target and to non-HDL-C or apoB when residual atherogenic burden is likely. Risk estimation tools are population-based and may under- or overestimate risk for an individual; clinical risk modifiers and patient characteristics should therefore be incorporated into treatment decisions.